Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Northeast Georgia Medical Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
University of Chicago
mi
from
Chicago, IL
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
RHHP/ Hope Cancer Center
mi
from
Terra Haute, IN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
RHHP/ Hope Cancer Center
mi
from
Terra Haute, IN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Toledo Community Oncology Program
mi
from
Toledo, OH
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Toledo Community Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Medical University of South Carolina
mi
from
Charlston, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Medical University of South Carolina
mi
from
Charlston, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Family Cancer Center
mi
from
Memphis, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Family Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated:  10/15/2013
Virginia Cancer Institute
mi
from
Richmond, VA
Trial of Poor Performance Status Patients (ToPPS)
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
Status: Enrolling
Updated: 10/15/2013
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  10/15/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 10/15/2013
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  10/15/2013
Clinical Research Facility
mi
from
San Antonio, TX
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 10/15/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated:  10/16/2013
Massachusetts General Hospital Mass General Hospital
mi
from
Boston, MA
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated: 10/16/2013
Massachusetts General Hospital Mass General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated:  10/16/2013
Research Medical Center Onc Dept
mi
from
Kansas City, MO
Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment
Status: Enrolling
Updated: 10/16/2013
Research Medical Center Onc Dept
mi
from
Kansas City, MO
Click here to add this to my saved trials
MRI Evaluation of the Breast Areolar Margin and Paryenchyma
MRI Evaluation to Assess the Relationship Between the Areolar Margin and Underlying Breast Paryenchyma Attachments to the Dermis
Status: Enrolling
Updated:  10/19/2013
Piedmont Hospital
mi
from
Atlanta, GA
MRI Evaluation of the Breast Areolar Margin and Paryenchyma
MRI Evaluation to Assess the Relationship Between the Areolar Margin and Underlying Breast Paryenchyma Attachments to the Dermis
Status: Enrolling
Updated: 10/19/2013
Piedmont Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin in Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  10/21/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin
Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin in Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 10/21/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Status: Enrolling
Updated:  10/23/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)
Status: Enrolling
Updated: 10/23/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center at Commack
mi
from
Commack, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan Kettering Rockville Centre
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated:  10/23/2013
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Status: Enrolling
Updated: 10/23/2013
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer
Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer
Status: Enrolling
Updated:  10/24/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer
Assessment and Rehabilitation of Cognitive Impairments in Pediatric Survivors of Cancer
Status: Enrolling
Updated: 10/24/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Endoscopic Therapy of Malignant Bile Duct Strictures
Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study
Status: Enrolling
Updated:  10/28/2013
Massachusetts General Hospital
mi
from
Boston, MA
Endoscopic Therapy of Malignant Bile Duct Strictures
Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study
Status: Enrolling
Updated: 10/28/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy
Comparison of Methods for Luminal Distention for on Demand Sedation Colonoscopy: Air Insufflation, Carbon Dioxide and Water-aided Colonoscopy. A Randomized Controlled Trial.
Status: Enrolling
Updated:  10/28/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy
Comparison of Methods for Luminal Distention for on Demand Sedation Colonoscopy: Air Insufflation, Carbon Dioxide and Water-aided Colonoscopy. A Randomized Controlled Trial.
Status: Enrolling
Updated: 10/28/2013
Sepulveda Ambulatory Care Center, VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
Mattel Children's Hospital
mi
from
Los Angeles, CA
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
Mattel Children's Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
Children's Healthcare of Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
Dana-Farber Cancer Institute/Children's Hospital Boston
mi
from
Boston, MA
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
Dana-Farber Cancer Institute/Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
University of Michigan
mi
from
Ann Arbor, MI
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
Cook's Children's Medical Center
mi
from
Forth Worth, TX
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
Cook's Children's Medical Center
mi
from
Forth Worth, TX
Click here to add this to my saved trials
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated:  10/31/2013
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool
Predictors of Adolescent Sperm Banking: Development of a Profiling and Referral Tool
Status: Enrolling
Updated: 10/31/2013
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Status: Enrolling
Updated:  11/8/2013
Medical Oncology Branch - Center for Cancer Research - National Cancer Institute
mi
from
Bethesda, MD
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Status: Enrolling
Updated: 11/8/2013
Medical Oncology Branch - Center for Cancer Research - National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Status: Enrolling
Updated:  11/8/2013
Endocrine Oncology - University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence
Status: Enrolling
Updated: 11/8/2013
Endocrine Oncology - University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Emergency Department-Based Palliative Care for Advanced Cancer Patients
Emergency Department-Based Palliative Care for Advanced Cancer Patients
Status: Enrolling
Updated:  11/11/2013
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Emergency Department-Based Palliative Care for Advanced Cancer Patients
Emergency Department-Based Palliative Care for Advanced Cancer Patients
Status: Enrolling
Updated: 11/11/2013
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
Palm Beach Cancer Institute
mi
from
West Palm Beach, FL
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
Palm Beach Cancer Institute
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
Georgia Cancer Specialists
mi
from
Atlanta, GA
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
Summit Medical Group
mi
from
Berkley Heights, NJ
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
Summit Medical Group
mi
from
Berkley Heights, NJ
Click here to add this to my saved trials
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated:  11/14/2013
Mid Dakota Clinic, PC
mi
from
Bismark, ND
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Status: Enrolling
Updated: 11/14/2013
Mid Dakota Clinic, PC
mi
from
Bismark, ND
Click here to add this to my saved trials
PRO#0118: Decitabine Plus Mini Flu-Bu
PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies
Status: Enrolling
Updated:  11/18/2013
Hackensack University Medical Center - John Theurer Cancer Center
mi
from
Hackensack, NJ
PRO#0118: Decitabine Plus Mini Flu-Bu
PRO#0118: A Phase I Study of Decitabin in Combination With Fludarabin and Busulfan as a Reduced Intensity Conditioning Regimen for the Treatment of Myeloid Malignancies
Status: Enrolling
Updated: 11/18/2013
Hackensack University Medical Center - John Theurer Cancer Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated:  11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD
Status: Enrolling
Updated: 11/19/2013
Texas Tech University Health Sciences Center at El Paso
mi
from
El Paso, TX
Click here to add this to my saved trials